Status:
COMPLETED
Double-blind and Placebo-controlled Study on Intervention Effect of Medium and Long Chain Fatty Acid Triglyceride on Glycolipid Homeostasis in Patients With Metabolic Syndrome and Mechanisms
Lead Sponsor:
Zhejiang University
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
40-70 years
Phase:
NA
Brief Summary
Double-blind and placebo-controlled study on intervention effect of medium and long chain fatty acid triglyceride on glycolipid homeostasis in patients with metabolic syndrome and mechanisms
Eligibility Criteria
Inclusion
- Diagnosed metabolic syndrome according to IDF diagnostic criteria;
- Rarely eating out of home;
- Aged between 40 and 70 years.
Exclusion
- Breastfeeding or pregnancy;
- History of heart disease, coronary heart disease, stroke, cerebral infarction, viral liver disease (hepatitis A, hepatitis B, etc.), chronic kidney disease (GFR\<60 ml/min) or cancer;
- Diabetic ketoacidosis or hyperketosis;
- Drug use has changed in the past six months;
- Taking insulin;
- Used MLCT edible oil in the past six months;
- Have participated in other clinical trials in the last three months.
Key Trial Info
Start Date :
May 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2023
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06210230
Start Date
May 22 2023
End Date
December 10 2023
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lanxi Traditional Chinese Medicine Hospital
Jinhua, Zhejiang, China, 321102